How should I manage a patient with restless legs syndrome (RLS) who reports that coffee at 8 pm alleviates symptoms but has developed augmentation on pramipexole?

Discontinue pramipexole immediately and transition to gabapentin or pregabalin—your patient's augmentation is a serious complication that will only worsen with continued dopamine agonist use, and her coffee ritual is likely a placebo effect or coincidental timing that should not influence evidence-based management.

Understanding the Clinical Situation

Your patient has developed augmentation, one of the most problematic complications of dopamine agonist therapy for RLS. The 2025 AASM guidelines explicitly recommend against the standard use of pramipexole due to this very risk 1. Augmentation occurs in 32-33% of patients on long-term pramipexole therapy 2, 3 and is characterized by:

• Earlier onset of symptoms during the day
• Increased symptom severity
• Anatomic spread to other body parts
• Shorter latency to symptom onset when at rest
• Paradoxical worsening despite dose increases

The Coffee Question: A Red Herring

The reported benefit from 8 PM coffee is almost certainly not therapeutic and should not guide your treatment decisions. Here's why:

• Caffeine is a known RLS exacerbator in most patients, not a treatment
• The timing (8 PM) would typically worsen evening symptoms, not improve them
• This likely represents placebo effect, coincidental timing with medication effects, or misattribution of symptom patterns
• No evidence supports caffeine as RLS therapy

Immediate Management Algorithm

Step 1: Initiate First-Line Therapy (Before Tapering Pramipexole)

Start gabapentin, pregabalin, or gabapentin enacarbil immediately 1. These carry strong recommendations from the 2025 AASM guidelines:

• Gabapentin: 300-600 mg, 1-2 hours before symptom onset, titrate up to 1800-2400 mg/day
• Pregabalin: 75-150 mg, 1-2 hours before symptoms, titrate to 300-450 mg/day
• Gabapentin enacarbil: 600 mg at 5 PM (extended-release formulation)

Critical point: Do NOT taper pramipexole yet. Adding the alpha-2-delta ligand first prevents the severe rebound RLS that occurs with dopamine agonist withdrawal 4.

Step 2: Check Iron Parameters

Order ferritin and transferrin saturation immediately:

• If ferritin ≤100 ng/mL or transferrin saturation <20%: Start ferrous sulfate 325 mg daily or every other day 1
• Consider IV ferric carboxymaltose 1000 mg (strong recommendation) for faster repletion 1
• Target ferritin >75-100 ng/mL

Step 3: Very Slow Pramipexole Taper (After 2-4 Weeks)

Once adequate symptom control is achieved with the gabapentinoid:

• Reduce pramipexole by no more than 0.125 mg every 2 weeks
• Expect temporary symptom worsening during taper
• May need to temporarily increase gabapentinoid dose during taper
• Complete discontinuation may take 2-3 months

Warning: Rapid dopamine agonist withdrawal causes profound rebound RLS and insomnia that can be intolerable 4.

Step 4: If Refractory After Gabapentinoid Trial

If symptoms remain uncontrolled despite adequate gabapentinoid dosing and iron repletion:

• Consider low-dose opioids (conditional recommendation, moderate evidence) 1
• Extended-release oxycodone 5-10 mg or methadone 5-10 mg daily 5
• Opioids are highly effective for augmented RLS and refractory cases 4, 6

Common Pitfalls to Avoid

1. Do not increase pramipexole dose: This worsens augmentation long-term despite temporary relief
2. Do not switch to another dopamine agonist: Ropinirole and rotigotine carry the same augmentation risk 1
3. Do not taper pramipexole before starting alternative therapy: Causes severe rebound symptoms 4
4. Do not dismiss the coffee claim dismissively to the patient: Acknowledge her observation while explaining the evidence-based approach

Addressing the Patient's Coffee Belief

When discussing with your patient:

• Validate that she noticed a pattern, but explain augmentation causes fluctuating symptoms that can create false associations
• Emphasize that continuing pramipexole will lead to progressive worsening requiring ever-higher doses
• Explain that proper treatment with gabapentinoids provides more reliable, sustainable relief
• She can continue her coffee if she wishes, but the treatment plan should follow evidence

Risk Factors Present in This Case

Your patient likely has additional augmentation risk factors to address 7, 3:

• Previous dopaminergic drug use (if applicable)
• Duration of pramipexole therapy
• Current pramipexole dose
• Possible iron deficiency (check labs)

The 2025 AASM guidelines represent a major shift away from dopamine agonists as first-line therapy specifically because of cases like yours 1. The moderate certainty evidence supporting this recommendation reflects extensive clinical experience with augmentation's devastating impact on quality of life.